AgeneBio, in collaboration with NIA, is studying whether AGB101 slows cognitive and functional impairment in people with prodromal Alzheimer’s disease. Prodromal Alzheimer’s is when a patient shows mild cognitive impairment due to the disease.
The study started in October 2018 and will be on till November 2022.
What’s AGB101?
It is a low-dose formulation of levetiracetam, an atypical anti-convulsant medication originally developed for the treatment of epilepsy. Participants will be randomized to receive a tablet of AGB101 or placebo, orally once a day once for 78 weeks. Participants will be assessed for cognitive and functional changes and clinical progression of disease.
Find out whether you or your loved one is eligible for the trial: https://www.nia.nih.gov/alzheimers/clinical-trials/agb101-mild-cognitive-impairment-due-alzheimers-disease
Leave a Reply